Refractory Diffuse Large B-Cell Lymphoma Clinical Trials

18 studies are recruiting for refractory diffuse large b-cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Duarte, California 7 Chicago, Illinois 5 New York, New York 4 Philadelphia, Pennsylvania 4 Richmond, Virginia 4 Sacramento, California 4 Columbus, Ohio 3 Indianapolis, Indiana 3 La Crosse, Wisconsin 3 Milwaukee, Wisconsin 3 Newberg, Oregon 3 Oklahoma City, Oklahoma 3 Oregon City, Oregon 3 Orland Park, Illinois 3 Portland, Oregon 3 Seattle, Washington 3 Tucson, Arizona 3

Studies now recruiting

  1. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Comprehensive Cancer Center, Duarte, California
    Locations
    9 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05272384 on ClinicalTrials.gov

  2. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (re…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Banner University Medical Center - Tucson, Tucson, Arizona
    Locations
    96 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06649812 on ClinicalTrials.gov

  3. Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

    This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refract…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
    Run by
    University of Washington

    See if you can join NCT06784726 on ClinicalTrials.gov

  4. Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

    This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a bispecific antibody,…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
    Locations
    3 in total
    Run by
    Yazeed Sawalha

    See if you can join NCT06536049 on ClinicalTrials.gov

  5. Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    This phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or has not responded to…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California Davis Comprehensive Cancer Center, Sacramento, California
    Run by
    University of California, Davis

    See if you can join NCT05052528 on ClinicalTrials.gov

  6. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

    This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Comprehensive Cancer Center, Duarte, California
    Locations
    7 in total
    Run by
    AIDS Malignancy Consortium

    See if you can join NCT05077527 on ClinicalTrials.gov

  7. Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal anti…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT05672251 on ClinicalTrials.gov

  8. Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

    This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapy in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previ…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California Davis Comprehensive Cancer Center, Sacramento, California
    Run by
    University of California, Davis

    See if you can join NCT06854159 on ClinicalTrials.gov

  9. Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

    This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X] or gemcitabine and oxaliplatin [Gem/Ox]) and autolog…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California Davis Comprehensive Cancer Center, Sacramento, California
    Run by
    University of California, Davis

    See if you can join NCT06905509 on ClinicalTrials.gov

  10. Epcoritamab-CAR T Cells for Large B-cell Lymphomas

    This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania
    Run by
    Abramson Cancer Center at Penn Medicine

    See if you can join NCT06458439 on ClinicalTrials.gov

  11. Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Many racial and…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06859008 on ClinicalTrials.gov

  12. Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

    This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Mayo Clinic in Rochester, Rochester, Minnesota
    Locations
    4 in total
    Run by
    Mayo Clinic

    See if you can join NCT03418038 on ClinicalTrials.gov

  13. Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

    This phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) with exposure to high-risk antibiotics who are receivi…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT07042438 on ClinicalTrials.gov

  14. B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

    This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of patients with B-cell hematologic malignancies that has come back after a peri…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic in Florida, Jacksonville, Florida
    Run by
    Mayo Clinic

    See if you can join NCT06191887 on ClinicalTrials.gov

  15. Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

    This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) or has not responded to previous treatment (refractory). Patients with relapsed or refractory disea…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT05800405 on ClinicalTrials.gov

  16. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Banner University Medical Center - Tucson, Tucson, Arizona
    Locations
    87 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT05633615 on ClinicalTrials.gov

  17. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetosta…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Banner University Medical Center - Tucson, Tucson, Arizona
    Locations
    104 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT05890352 on ClinicalTrials.gov

  18. DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Compassionate Cancer Care Medical Group, Fountain Valley, California
    Locations
    50 in total
    Run by
    ImmunoVaccine Technologies, Inc. (IMV Inc.)

    See if you can join NCT04920617 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.